CALL FOR ABSTRACTS

DIA 2027 GLOBAL ANNUAL MEETING

SAN DIEGO, CA | JUNE 28-JULY 1

Innovate, Engage, Educate:

Your Guide to Abstract Submission for DIA 2027

SUBMISSION DEADLINE:

SEPTEMBER 17

TABLE OF CONTENTS

About the *DIA 2027 Global Annual Meeting* 3

Elevating Patient Perspectives in DIA 2027 Content 3

Submit with Purpose: Priority Topics, Session Formats, and Responsibilities for DIA 2027 4

DIA Priority Topics 4

Types of Abstracts 4

LIFT Series and Therapeutic Pathways 5

Session Chair Responsibilities 6

General Submission Requirements 9

Submission Deadline 9

Abstract Eligibility and Guidelines 9

Notification Timeline 9

Submission Tips 9

Frequently Asked Questions 10

2027 Track Offerings 11

ABOUT THE *DIA 2027 GLOBAL ANNUAL MEETING*

Make Better Decisions Faster for Patients

DIA 2027 is where the global life sciences community examines the choices, tools, and operating models that are reshaping how therapies are developed, evidence is generated, and patients gain access to care worldwide. Industry, regulators, academia, and patients will come together not just to share updates, but to interrogate what works, what does not, and what must change next across discovery, development, safety, and access.

This is more than a meeting. It is a working forum for people who are accountable for real decisions and real outcomes. The conversations that start here are designed to translate insight into measurable progress in regulatory science, clinical practice, and patient experience.

DIA's mission is to turn professional insight into real-world impact. The 2027 program will spotlight diverse perspectives, elevate global expertise, and focus on solving complex, cross-functional challenges with bold thinking and practical solutions that attendees can carry back to their organizations.

We encourage abstract submissions that move beyond "what's new" to show:

- How AI, data, and evidence strategies are being operationalized in practice.
- How organizations are de-risking decisions and accelerating access.
- Lessons from implementation, including failures and course corrections.
- Concrete examples of diversity, equity, inclusion, and patient partnership that changed outcomes.
- Cross-stakeholder collaboration that bridges scientific, regulatory, and commercial realities.

We are looking for sessions that:

- Encourage audience interaction and engagement.
- Create dynamic discussion and bring forward diverse perspectives.
- Share practical, real-world solutions attendees can apply immediately.
- Surface tradeoffs and unresolved questions, not just conclusions.
- Address timely challenges and emerging opportunities across the life sciences.

Whether you are sharing a big-picture vision or day-to-day strategies, your work can help reimagine the future of healthcare and the evidence, policies, and operations that support it. Join us in San Diego to be part of this global conversation and help lead the way forward.

Elevating Patient Perspectives in DIA 2027 Content

DIA is committed to including the voice and lived experience of patients at DIA 2027. Through DIA's Patient Partner initiative, patient communities will be embedded across content formats, not confined to a single track or session type. We strongly encourage patients and patient representatives to submit abstract proposals to all relevant tracks; the Annual Meeting Program Committee (AMPC) will actively look for and prioritize these contributions during the abstract selection process.

SUBMIT WITH PURPOSE: PRIORITY TOPICS, SESSION FORMATS, AND RESPONSIBILITIES FOR *DIA 2027*

Priority Topics

SUBMIT WITH PURPOSE: PRIORITY TOPICS, SESSION FORMATS, AND RESPONSIBILITIES FOR DIA 2027

DIA Priority Topics

The DIA Science Team has identified cross-cutting priority topics that reflect high-stakes, emerging areas across the global life sciences ecosystem. Submitters are strongly encouraged to anchor their abstracts in one or more of these areas, as they represent current scientific, regulatory, and innovation challenges that align with DIA's mission and DIA 2027 objectives.

- AI and Real-World Evidence (RWE) in Medical Product Development that improve decision quality across development, safety, and access.
- Drug Development for Chronic Diseases: Modern development models for chronic, long-duration, and multi-morbidity care.
- Innovative Approaches to Clinical Trials: Trial designs and operations that reduce burden, increase speed, and improve quality.
- Personalized Medicine: Precision approaches that better define the right patient, dose, and endpoint.
- Cell and Gene Therapy: CMC standards, comparability, regulatory harmonization, and global patient access.
- Regulatory reliance, collaboration, and practical pathways to faster, more equitable access.

These priorities will serve as the foundation for DIA 2027. Track Chairs have identified complementary themes within each educational track to guide abstract submissions and highlight topics they are particularly interested in exploring further this year.

Abstracts that align with one or more of these priority areas—through novel approaches, collaborative models, or bold scientific inquiry—will be prioritized during review. Preference will also be given to submissions that reflect interdisciplinary thinking, address real-world challenges in meaningful ways, and propose high-level expert speakers who bring credible, current, and diverse perspectives to the discussion.

Types of Abstracts

DIA 2027 welcomes **five** types of abstract submissions:

1. Session
2. Forum
3. Workshop
4. Half-Day Pre-conference Short Course
5. Full-Day Pre-conference Short Course

Each format has its own structure and requirements. Abstracts must follow the defined format and cannot be altered. You may submit more than one abstract.

LIFT SERIES AND THERAPEUTIC PATHWAYS AT DIA 2027

LIFT Series: Accelerating Innovation from Idea to Impact

The LIFT Series (Linking Innovation, Funding, and Translation) returns to DIA 2027 after a successful launch in Philadelphia, bringing together emerging innovators, biotech and technology companies, investors, regulators, and life sciences leaders to accelerate the next generation of healthcare solutions. As part of DIA 2027, LIFT will showcase groundbreaking ideas, novel technologies, transformative approaches that are shaping the future of drug development and healthcare, and collaborative partnerships that transform promising ideas into real-world impact.

We encourage abstract submissions that explore:

- Startup and entrepreneurial journeys
- Emerging technologies and digital health innovations
- AI-enabled solutions for life sciences
- Venture capital and investment perspectives
- Translating research into commercial products
- Academic-industry collaborations
- Innovation ecosystems
- Scaling new technologies globally
- Regulatory pathways for innovative companies
- Lessons learned from bringing disruptive ideas to market

Selected submissions may be featured within LIFT Series programming at DIA 2027, providing an opportunity to share your vision with a global community of life sciences professionals, potential partners, investors, and decision-makers.

Therapeutic Pathways

Building on the success of the Therapeutic Pathways introduced at DIA 2026, DIA 2027 will continue to highlight emerging science, innovation, and collaboration through focused programming pathways designed to bring together experts across the healthcare ecosystem.

For DIA 2027, our Therapeutic Pathways will spotlight Neurodegenerative Disease and Aging and Cell and Gene Therapy (CGT) and Rare Disease - two rapidly evolving areas with significant opportunities and challenges across research, development, regulation, access, and patient impact.

Abstract submissions aligned with these Therapeutic Pathways are encouraged and will be considered for preferred placement within these high-impact program areas. We invite you to share your expertise, insights, and innovations that are advancing the future of healthcare.

Session Chair Responsibilities

The primary contact for each abstract submission is considered the Session Chair and will be responsible for:

- Following all program development guidelines and deadlines (details provided upon acceptance)
- Adhering to the speaker recruitment guidelines, depending on the length of your session
- Ensuring speaker diversity including but not limited to professional status, cultural background, demographics, as well as lived experiences and identity

  Important – DIA does not permit more than one speaker from the same organization
- Communicating roles and expectations to all speakers
- Reviewing and coordinating speaker presentation materials (PowerPoint templates will be provided)
- Serving as the emcee during the live session: introducing the topic and speakers, managing timing, and facilitating audience Q&A
- Proposing the session's learning level (Basic, Intermediate, or Advanced)
  - Basic: Appropriate for individuals new to the topic/subject area.
  - Intermediate: Appropriate for individuals who already have a basic understanding of the topic/subject area.
  - Advanced: Appropriate for individuals with an in-depth knowledge of the topic/subject area.

(DIA reserves the right to adjust as deemed appropriate)

If submitting a Workshop proposal, additional expectations include:

- Designing interactive, hands-on learning components such as group exercises, simulations, or live demonstrations
- Planning for 75–100 attendees.

Priority will be given to proposals that offer engaging, nontraditional approaches to content delivery.

If your abstract is accepted, you will be notified of the session's duration.

Extended Session Blocks

Select sessions with innovative or interactive formats may now be scheduled for up to 75 minutes.

Session

A session is delivered lecture-style from the podium, typically with one to three speakers. These sessions are focused on delivering structured, expert-driven content on a specific topic.

Formats may include:

- **Lightning Talks / PechaKucha / Ignite Sessions:** These formats involve short, timed presentations with a strict limit on slides and time per slide (e.g., 20 slides, 20 seconds per slide). This forces presenters to be incredibly concise, dynamic, and focused, keeping energy high.
- **Themed Sessions:** A session built around a creative theme (e.g., "Solve the Mystery," "Escape Room Challenge") that integrates the content into an engaging narrative.
- **MythBusters / Fact vs. Fiction:** A fun and educational session that tackles common misconceptions in the field, supported by data and insights. These can be designed as a series of short mini-topics that each speaker addresses.
- **Deep Dive / Masterclass:** Ideal for advanced-level content, this format allows one or two speakers to explore a complex topic in detail, offering real-world applications and take-home tools.
- **Case Study:** This format invites presenters to walk participants through a real-world business case from concept to outcome. Proposals should focus on a specific challenge, decision point, or innovation, and highlight how the situation was navigated, successfully or not.
- **TED Talk Style:** This format features a compelling, thought-provoking talk. The focus should be on sharing a bold idea, personal insight, or unique perspective that challenges conventional thinking or sparks conversation. The tone should be energetic, engaging, and accessible, less academic lecture, more storytelling with a purpose.

If you plan to incorporate interactive elements into your proposed session(s), forum(s), and workshop(s), please include your interactivity plan in the Abstract Details section of your submission.

We understand this will be a high-level overview rather than a detailed implementation plan, but we'd like to know what interactive approaches you're considering.

Helpful hint!
Plan your submission separately and in advance by using this **Session abstract template**. *Read a* **sample session abstract**.

Forum

A forum is a dynamic and interactive format, designed to foster open dialogue and exchange of ideas among participants with the audience. Forums prioritize multiple perspectives and active attendee engagement and typically include a Chair and up to three panelists.

Forum Key Features:

- **Interactive Dialogue:** Forums typically focus on specific issues or topics, allowing participants to engage in robust discussions. This setup is perfect for exploring multiple viewpoints and brainstorming solutions.
- **Facilitator-Led:** A facilitator usually moderates the session, guiding the discussion, posing questions, and ensuring that everyone has a chance to contribute. Think of it like a town hall meeting where everyone gets a say.
- **Diverse Perspectives:** Forums often bring together people from various backgrounds or sectors, promoting a rich tapestry of ideas and experiences. This diversity enhances the depth and breadth of the discussion.

Formats may include:

- **Debates:** Two or more speakers present opposing viewpoints on a topic, followed by rebuttals and audience engagement. This can be highly engaging and stimulate critical thinking.
- **Panel Discussions:** These are the "talk shows" of the forum world. A group of experts or enthusiasts gather to share insights, often moderated by a host who keeps the conversation lively and engaging. It's kind of like tuning into your favorite podcast but with a live audience.
- **Ask-the-Expert:** These often follow a presentation and allow attendees to tap into the experts' insights and dig deeper into the subject matter. It's like the after-show where the fans get to ask their burning questions.

If you plan to incorporate interactive elements into your proposed session(s), forum(s), and workshop(s), please include your interactivity plan in the Abstract Details section of your submission.

We understand this will be a high-level overview rather than a detailed implementation plan, but we'd like to know what interactive approaches you're considering.

Helpful hint!
Plan your submission separately and in advance by using this **Forum abstract template**. *Read a* **sample forum abstract**.

Workshop

A workshop is delivered in a 60- or 75-minute interactive/simulation or roleplaying format. Instead of just listening, attendees actively participate in exercises, group activities, or problem-solving. This is crucial for skill development and ensures attendees leave with tangible takeaways.

Formats may include:

- **Roleplaying or Simulation-Based:** Attendees take on specific roles (e.g., customer, executive, regulator) to explore different perspectives. Participants engage in a realistic scenario (e.g., crisis response, product launch, negotiation).
- **Case Study Challenge:** Participants analyze a real or fictional case and work in teams to solve a problem. Includes group presentations and peer feedback. Ideal for strategic thinking, decision-making, and applying frameworks.
- **Design Sprint:** Condensed version of a design sprint focused on ideation and prototyping. Teams rapidly brainstorm, sketch solutions, and present mock-ups. Great for innovation, product development, or process improvement.
- **World Cafe:** Rotating small-group discussions around key questions. Each round builds on the previous, capturing insights on shared templates. Encourages cross-pollination of ideas and inclusive dialogue.
- **Skills Lab:** Hands-on practice of a specific skill (e.g., coaching, feedback, storytelling). Includes demos, paired practice, and real-time feedback. Participants leave with a refined skill and a personal action plan.

Helpful hint! Plan your submission separately and in advance by using this **Workshop abstract template**. *Read a* **sample workshop abstract**.

Pre-conference Short Courses

A Short Course is a "hands-on," interactive learning experience for a group of 25-50 attendees.

Formats may include:

- **Learning Labs:** Participants work through real-world scenarios, case studies, or mock regulatory submissions. Great for problem-solving and team interaction.
- **Bootcamp:** A structured, fast-paced learning experience meant to build a specific skill or competency. Could be tech, process, or compliance focused.
- **Toolkit Session:** Attendees leave with templates, checklists, or workflows they can immediately use. Ideal for newer professionals or those trying to improve a process.
- **Ask Me Anything (AMA) + Skill Station:** Blend of expert-led Q&A and hands-on workstations or mini breakout sessions, each covering a different part of a process or tool.



Tools Available

- Onsite Learning Tools Include: Live Polling & Q&A - Using tools like Slido, and the DIA app to ask real-time questions, gather audience opinions, and allow attendees to submit and upvote questions for the speaker. Displaying results instantly fosters engagement.
- Virtual Learning Tools for Short Courses include: Zoom breakout rooms, Mural, polls, or live documents.
- DIA will work with Session Chairs of available tools and how to engage with the audience throughout the planning process.

Half-Day Pre-conference Short Course

- Course duration is three hours and 15 minutes (3hrs 15mins) of instruction
- Will have a lead instructor and no more than one co-instructor
- Conducted virtually within the two weeks prior to *DIA 2027*. DIA will consult with the chair to confirm the date and time of the course.

Full-Day Pre-conference Short Course

- Course duration is six hours and 30 minutes (6hrs 30 min) of instruction
- Will have a lead instructor and no more than two co-instructors
- Held in person onsite, one day prior to *DIA 2027*.

Helpful hint!
Plan your submission separately and in advance by using this **short course abstract template**.

GENERAL SUBMISSION REQUIREMENTS

Please read all instructions carefully. Incomplete or incorrect submissions will not be considered.

Submission Deadline

All abstracts must be submitted online at DIAglobal.org/Abstract by **September 17, 2026, at 11:59 PM ET**. **This deadline will not be extended**.

On the abstract submission homepage, be sure to select the **General Session** submission link.

Abstract Eligibility and Guidelines

- Abstracts must not promote or recommend specific products or services. Please review DIA's Policy Concerning Promotion of Products and Services from the Podium for full details.
- **Only full Session, Forum, Workshop, or Short Course abstracts** will be accepted. *Individual presentation abstracts will not be reviewed.*
- After the abstract is accepted, the abstract author is responsible for recruiting speakers, following the speaker guidelines in Speakers Corner.
- **No more than one participant from the same company** may be included in any single session, including Chairs and speakers.
- Abstract titles must clearly and concisely reflect the session content. DIA reserves the right to edit titles for clarity or alignment with overall program themes.
- Co-Chairs and Co-presenters (two speakers presenting the same content) are not permitted.

Notification Timeline

Submitters will be notified of their abstract status by the end of January 2027.

Please note: DIA and the AMPC may request revisions to your abstract, including adjustments to the topic focus, merging with other submissions, or changing the session's difficulty level.

Submission Tips

- Still have questions? View this 10 minute video about DIA 2027 and the call for abstracts process.
- Don't wait until the last day to submit. Website traffic is usually heavy, which can lead to technical issues.
- Avoid using your browser's "back" button during the submission process.
- **Be sure to click "Submit" at the end. If you don't receive a confirmation email, your abstract was not received.**

Questions?

Contact DIA at AnnualMeetingProgram@DIAglobal.org

FREQUENTLY ASKED QUESTIONS

The following are helpful hints and frequently asked questions regarding abstract submissions for the *DIA Global Annual Meeting*.

Q: What is the difference between a session and a forum?

A: **Session:** Think of a session as your typical classroom setup. It usually involves a presenter or a panel sharing information on a specific topic. Participants are primarily listeners, absorbing the content through lectures or presentations. Interaction is often limited to Q&A segments at the end, much like asking questions after a movie screening.

Forum: A forum is more like a lively town hall meeting. Here, the focus is on dialogue and exchange among attendees. Rather than just listening, participants actively engage, debate, and share their own insights. It's less about being talked to and more about talking with others. Picture sitting around a table at a family dinner where everyone's voice matters.

Key Differences

- **Format:** Sessions are structured and presenter-driven, while forums are flexible and participant-driven.
- **Interaction:** Sessions have limited interaction, whereas forums thrive on engagement and discussion.
- **Purpose:** Sessions aim to inform, while forums aim to explore and solve.

Q: I submitted a topic during the Call for Topics, and it appears under the suggested topics for the *Global Annual Meeting*. Do I still have to submit a session abstract?

A: Yes, you must submit an abstract to be considered as a chair for *DIA 2027*.

Q: What is a Track-Specific Theme?

A: Track-specific themes support the broader goals of each educational track. They represent the ongoing and foundational themes relevant to that area.

Q: May an author submit more than one abstract?

A: Authors may submit multiple abstracts. *Do not submit the same exact abstract more than once.*

Q: What information is required from the author?

A: Authors are required to include:

- Full contact information
- Participant disclosure information and speaker authorization for use of presentation materials, which allows DIA to distribute your presentation to other *DIA 2027* registrants

Q: Can there be more than one author name?

A: No, only one author name may be submitted.

Q: What constitutes a quality abstract?

A: Information provided in the "Abstract Details" section should include specific details or data to support your abstract submission:

- Unbiased content that does not promote a product, service, or organization; abstracts deemed to be promotional will be excluded from consideration
- Innovative and cutting-edge information, or new developments related to the topic
- Real world applications, such as case studies or demonstrations
- A global perspective
- A session or presentation title that is compelling and attractive to potential attendees
- Content that is cross-functional and interdisciplinary, if possible/appropriate
- A clear target audience with clear learning objectives
- Plans for interactivity between the speakers and audience.

Q: Do I have to use the DIA website to submit the abstract?

A: Yes. Only abstracts submitted via the DIA website will be considered for inclusion in the program. You are encouraged to prepare your abstract in a separate document prior to submitting on our website. You can then copy and paste your abstract information from the prepared document as plain text.

Q: Are there abstract templates or samples available?

A: Yes, there is a sample abstract as well as a form that you may use to prepare your abstract in advance.

General abstract template
Short course abstract template
Session abstract sample
Forum abstract sample
Workshop abstract sample

Q: May someone else submit the abstract on my behalf?

A: Yes: For **sessions**, **forums**, and **workshops**, a submitter will have the option to complete author information even if they will not be the designee onsite in San Diego.

Q: When will I be notified if my abstract has been accepted?

A: Authors will be notified by the end of January 2027. Accepted abstract authors are requested to confirm their participation as a chair or speaker with DIA by logging into Speakers Corner. Instructions for accessing Speakers Corner will be provided via the acceptance eMail.

TRACK 1: **CLINICAL SAFETY, PHARMACOVIGILANCE, AND RISK MANAGEMENT**

This track focuses on how organizations navigate the evolving global landscape of clinical safety, pharmacovigilance, and risk management for medical products, including biopharmaceuticals, advanced therapies, and medical devices. Sessions examine proactive approaches to identifying, assessing, communicating, and mitigating safety risks while incorporating the patient voice throughout the pharmacovigilance ecosystem. Forward-thinking discussions highlight the application of emerging technologies, real-world data sources, and advanced analytical techniques to strengthen safety signal detection, enhance benefit-risk assessment and communication, and optimize risk management strategies across the product lifecycle as regulatory expectations evolve, and medical product development becomes increasingly global.

Priority Topics / Themes

- Global Pharmacovigilance Regulations and Cross-Industry Collaborations: Updates on evolving regulatory requirements, harmonization efforts, and collaborative approaches worldwide.
- Patient Engagement and Preference Studies in Safety and Risk Management: Practical approaches to embedding patient perspectives and formal preference methodologies into safety monitoring, benefit-risk decisions, and access planning. This includes the use of scientifically validated patient preference studies conducted in parallel with clinical trials to strengthen product dossiers and support regulatory and reimbursement decisions.
- Measuring the Impact of Risk Management and Mitigation Strategies: Evaluating the effectiveness of risk minimization measures, labeling, and safety communications throughout the product lifecycle.
- AI and Technology-Enabled Safety Surveillance and Analytics: Use cases on leveraging AI for improved pharmacovigilance operations including case management, safety signal detection, noise reduction, assessments, and proactive risk mitigation. Practical controls for compliance, oversight, and inspection readiness.
- Pharmacovigilance for Combination Products, Medical Devices, and Advanced Therapies: Unique monitoring considerations for diverse product types, including generics, biosimilars, and ATMPs.
- Special Populations in Pharmacovigilance: Tailored safety monitoring and risk mitigation strategies for pediatrics, pregnancy, rare diseases, and underrepresented populations.
- Pharmacogenomics and Personalized Safety Monitoring: Using genetic insights to predict, monitor, and manage adverse events, enhancing individualized patient safety.

Key Questions to be Addressed

How can global pharmacovigilance frameworks and collaborations improve consistency, speed, and quality in safety monitoring and reporting, and improve the utilization of reportable information by health authorities?

How can structured patient preference studies enhance benefit-risk decision-making, access planning, and communication with regulatory authorities?

How can emerging technologies improve signal management and proactive risk mitigation?

What strategies best measure the real-world effectiveness of risk management plans and mitigation measures to ensure true impact on patient safety across diverse populations and products?

TRACK 2: **CLINICAL TRIAL OPERATIONS AND INNOVATION**

This track examines how clinical trials are actually executed and what it takes to enable change. Clinical operations is being rebuilt in real time: operating models are reorganizing around digital capability, AI is being asked to prove measurable impact rather than promise it, sponsors are rebalancing what they run in-house, and sites and participants continue to absorb burden the industry has not yet solved. Sessions bring together sponsors, sites, regulators, CROs, and patients across regions to confront these problems with evidence, metrics, candid accounts of what failed alongside what worked, and practical approaches to cost, complexity, enrollment, and data. Attendees will leave with frameworks, benchmarks, and applied approaches they can put to work immediately within their own organizations.

Priority Topics / Themes

- Innovative Approaches to Accelerating Clinical Development: Faster, leaner, and smarter approaches to bringing new treatments to patients.
- New Digital Operating Models in Clinical Development: AI, automation, and digital technologies transforming clinical trial execution.
- AI in Trial Execution – Is It Working?: Real-world applications, lessons learned, governance, and measurable impact.
- Clinical Operations Workforce and Talent: Building future-ready teams through leadership, workforce development, and change management.
- Protocol Design, Complexity, and Feasibility: Designing operationally feasible studies that balance scientific and executional considerations.
- Site Selection and Trial-to-Site Matching: Optimizing site identification, activation, performance, and strategic partnerships.
- Sponsor, Site, and CRO Collaboration: Strengthening partnerships, governance, and collaboration to improve trial delivery.
- Patient Partnership, Recruitment, and Retention: Integrating patient perspectives to improve study design, enrollment, and retention.
- Study Start-Up, Vendor Selection and Trial Delivery: Streamlining feasibility, vendor selection, activation, and operational readiness to accelerate study execution.
- Clinical Data Foundations and Infrastructure – Build vs. Buy: Evaluating data platforms, integration strategies, and technology infrastructure.
- Operational Excellence, Oversight, and Risk Management: Applying quality, governance, vendor oversight, and risk-based approaches to trial execution.
- Clinical Trial Costs, Productivity, and Technology Investment: Optimizing efficiency, technology investments, and operational performance.
- Global Clinical Development Strategy and Policy: Navigating multi-regional trials, evolving regulatory landscapes, and global operational challenges.

Key Questions to be Addressed

How can organizations accelerate clinical development while maintaining quality, compliance, operational excellence, and patient safety?

How are AI, automation, digital technologies, and new operating models transforming clinical trial execution, and where are they delivering measurable value?

How can sponsors, CROs, sites, vendors, and patients collaborate more effectively to improve protocol design, study start-up, recruitment, retention, and trial delivery?

What innovative strategies are improving workforce capabilities, site selection, operational performance, and technology investments to deliver more efficient clinical trials?

How are evolving global policies, regulatory expectations, and geopolitical changes shaping multi-regional clinical development and the future of clinical operations?

TRACK 3: **DATA, TECHNOLOGY AND AI**

This track focuses on harnessing the power of data, technology, and AI to transform drug development, regulatory decision-making, and patient access to therapies. Sessions explore innovations in data capture, curation, integration, and novel methods of evidence generation across the product lifecycle, from clinical trials to post-market settings, while addressing emerging challenges in governance, transparency, risk management, oversight, equity, and responsible use of clinical technologies, including digital health technologies and AI. While Track 10 addresses the frameworks and analytical strategies that transform those data into actionable evidence, this track focuses on the generation, curation, integration, and operational enablement of data. This track also highlights the role of real-world evidence, policy-driven data innovation, and AI-enabled insights to accelerate development, enhance regulatory submissions, and inform healthcare decision-making globally.

Priority Topics / Themes

- Driving Regulatory Acceptance of AI-driven Endpoints Beyond Traditional Endpoints: regulatory acceptance of AI-derived imaging endpoints, validation frameworks, and evidentiary requirements.
- Foundational Models and Multimodal AI for Drug Development: multimodal AI, generalizable imaging foundational models, and regulatory considerations for continuously evolving models.
- Towards Regulatory Acceptance of Digital Endpoints: balancing global health authority perspectives, lessons learned from agency interactions, documentation requirements, and evidence standards.
- Best Practices for AI Disclosure: insights into transparent disclosure to health authorities and patients on AI use to derive clinical insights, development clinical trial documentation, and submission-quality evidence.
- Governance of AI Implementations and Systems: Successful methods to foster innovation while balancing technological, safety, risk management, and data science standards within regulated and evolving spaces.
- Global, Harmonized Approaches Towards AI Applications in Drug Development: balancing global health authority expectations and driving reconciliation to power innovation.
- Data Standards and Interoperability: Driving multi-stakeholder collaboration through standardized data frameworks, ensuring quality, integrity, and cross-border data sharing.
- Regulatory Agency Digital Transformation: Strengthening Regulatory Systems Through Global Collaboration.

Key Questions to be Addressed

How can AI-generated evidence achieve regulatory acceptance in drug development and clinical research?

How do we responsibly deploy advanced AI technologies, including foundation models and agentic AI, across the global drug development ecosystem?

What governance, transparency, and trust frameworks are needed for AI in drug development and successfully regulatory interactions?

How can data standards, interoperability, and global collaboration accelerate innovation while maintaining quality and compliance?

How do we ensure that advancement in AI and novel technologies is accessible to all?

How should regulators and industry validate, govern, and monitor advanced technology, such as generative AI and large language models, used in drug development and regulatory activities?

What privacy-preserving and federated data-sharing approaches can support global collaboration while maintaining regulatory confidence in data quality, provenance, and auditability?

TRACK 4: **MEDICAL AFFAIRS AND SCIENTIFIC COMMUNICATION**

This track examines global perspectives from Medical Affairs professionals and scientific communicators across the life sciences industry. Sessions highlight best practices and emerging trends in medical writing, regulatory and scientific content development, field medical activities, and stakeholder engagement, with a focus on delivering high-quality and compliant communications, leveraging technology and AI, strengthening cross-functional collaboration, and advancing project management and leadership capabilities throughout the product lifecycle.

Priority Topics / Themes

- AI-Native Medical Affairs and Scientific Communications: Provide insights on how AI is reshaping scientific content creation, review, delivery, discovery, and measurement, governance, including practical strategies for responsible, effective, and scalable implementation.
- Future of Medical Writing in a Rapidly Changing Environment: Share perspectives on how medical writing is evolving in response to AI, global regulatory change, content automation, and growing expectations for speed, quality, and strategic business impact. Highlight where human expertise remains essential and where automation can create efficiencies.
- Content Standardization, Governance, and Scale: Discuss approaches for implementing scalable content standards, governance models, digital protocols, and operating approaches that improve consistency, compliance, reuse, and efficiency.
- Personalized Scientific Content and Stakeholder Engagement: Provide insights on how whether personalized medicine requires more personalized scientific content, and how Medical Affairs can tailor education, communications, and engagement for different stakeholders without compromising accuracy or compliance.
- Field Medical in the Age of AI: Highlight how AI is changing the role of Field Medical, including how teams identify insights, prepare for scientific exchange, support KOL engagement, and demonstrate value in an increasingly digital environment. Explore the evolving competencies needed for MSLs, payer MSLs, and other medical affairs and scientific communication professionals.
- Patient-Centric Scientific Communications and AI: Highlight how Medical Affairs and scientific communications teams can ensure patient-facing materials, informed consent content, and AI-enabled communications are understandable, transparent, inclusive, and trustworthy.
- Trust and Transparency in Regulatory Affairs: Discuss emerging expectations for transparency, data sharing, representation, fair access, patient centricity, and industry accountability throughout regulatory documents, drug dossiers, and submissions.
- Education Continuums and High-Impact Scientific Exchange: Share successful models on how organizations can create connected education journeys for KOLs, clinicians, patients, and other stakeholders, moving from one-time content delivery to sustained scientific learning and engagement.
- Medical Affairs Leadership in an Era of Influence, Misinformation, and Public Trust: Provide insights on how Medical Affairs can lead credible patient and clinician education in a world shaped by influencers, digital channels, misinformation, disinformation, and rapidly shifting public expectations.

Key Questions to be Addressed

How can medical writers leverage AI, digital capabilities, and new technologies to improve scientific exchange, stakeholder experience, and organizational impact while maintaining trust, compliance, and scientific integrity?

What skills need to be developed to take advantage of emerging technologies?

What operating models, governance approaches, capabilities, and cross-functional partnerships are needed to scale innovation, standardization, and content excellence across the organization?

How can organizations create more personalized, relevant, and connected scientific engagement and education experiences for healthcare professionals, patients, caregivers, and other stakeholders?

TRACK 5: **PRECISION MEDICINE, COMBINATION PRODUCTS AND DIAGNOSTICS**

This track explores the convergence of medicines, diagnostics, and medical device technologies to advance precise medicine and improve patient outcomes. Sessions highlight advances in combination products, biomarkers, companion diagnostics, translational medicine, radioligand therapies, novel therapy platforms, and next-generation drug delivery systems that are reshaping therapeutic development. The track examines strategies for compound selection, preclinical and clinical development, optimized dosing, and innovative trial approaches that strengthen evidence generation and support informed decision-making. Additional sessions address commercialization, manufacturing, pharmacovigilance, and post-market considerations, while exploring global regulatory developments, emerging technologies, public policy, cross-sector collaboration, and early integration of the patient voice across diverse therapeutic areas, including rare diseases.

Priority Topics / Themes

- Complex Generics and Combination Products: Challenges in generic drugs, biosimilars, device integration, labeling, and regulatory considerations for combination product development.
- Radioligand Therapies (RLTs): Advances in radiopharmaceutical development, regulatory considerations, manufacturing, clinical development, and precision treatment strategies.
- Novel Therapy Platforms and Technologies: Emerging modalities including targeted cell and gene therapies, RLTs, rare disease therapies, and advanced drug delivery technologies.
- Global Developments in Diagnostics and Companion Products: Regional and international regulatory developments impacting diagnostics, companion diagnostics, AI-enabled regulations, and global initiatives.
- Translational Medicine and New Approach Methodologies (NAMs): Strategies for validation and integration of NAMs, case studies demonstrating preclinical-to-clinical translation, and their emerging role in the drug development pipeline.
- Digital Technology and AI in Precision Medicine: Applications of AI, digital twins, advanced analytics, and digital technologies to support diagnosis, targeted therapies, and precision medicine.
- Public Policy and Emerging Trends: Global policy developments affecting precision medicine, translational science, diagnostics, combination products, and emerging technologies.
- Pharmacovigilance for Combination Products, Medical Devices, and Advanced Therapies: Safety monitoring and lifecycle management for combination products, medical devices, radiopharmaceuticals, generics, biosimilars, and advanced therapies.

Key Questions to be Addressed

How are advances in precision medicine, combination products, diagnostics, radioligand therapies, and emerging therapeutic platforms transforming drug development and patient care?

How can organizations integrate biomarkers, companion diagnostics, AI, digital technologies, and translational science to accelerate personalized therapies and improve clinical decision-making?

How are evolving global regulations, public policy, and cross-sector collaboration shaping the development, commercialization, and lifecycle management of combination products, diagnostics, and advanced therapies?

What strategies strengthen evidence generation, manufacturing, pharmacovigilance, and patient engagement across the development and lifecycle of precision medicines and combination products?

TRACK 6: **PROFESSIONAL DEVELOPMENT AND PROJECT, PROGRAM AND PORTFOLIO MANAGEMENT**

This track provides opportunities for life sciences professionals to enhance their leadership capabilities, career development strategies, and project, program, and portfolio management expertise to deliver successful outcomes in an evolving industry landscape. It welcomes content across two focus areas: Professional Growth and Leadership Development, and Project, Program, and Portfolio Management & Strategic Leadership.

Professional Growth and Leadership Development Themes: Topics focused on career and leadership growth, communication in regulated and scientific environments, business acumen, critical thinking, and organizational savvy. Includes leveraging technology such as AI, virtual reality, learning management systems, and microlearning, applying ethical principles to technology use, and understanding how organizational culture shapes performance, promotion, and career advancement.

Project, Program, and Portfolio Management & Strategic Leadership Themes: Topics focused on value realization with strategy, planning, and execution across the lifecycle. This includes and is not limited to: project management skills, new ways of working with novel therapeutics, emerging capabilities, new tools (e.g., AI) and flexing leadership styles to navigate an evolving industry landscape. Project Managers increasingly need know-how to drive organizational transformation, expand value and access in emerging markets, and to foster innovation and acceleration.

Whether building individual skills, advancing team performance, or delivering complex programs, this track equips professionals with the knowledge, strategies, and tools to succeed in a global, regulated, and rapidly changing environment.

Priority Topics / Themes

Professional Development & Leadership Themes

- Professional, Personal, and Leadership Growth: Developing resilience, leading through ambiguity and change, managing up and across functions, and building sponsor, ally, and mentor relationships.
- Strategic Career Planning and Workforce Evolution: Designing and owning your career path through upskilling, reskilling, succession planning, internship and apprenticeship models, and connecting career growth to enterprise value.
- Communication and Influence in Regulated and Scientific Environments: Building credibility, preparing for regulatory authority interactions, and strengthening scientific and regulatory writing across global teams.
- Thought Leadership, Executive Presence, and Personal Brand: Developing a credible professional identity and point of view through speaking, publishing, networking, internal influence, and digital presence to expand impact, strengthen career mobility, and position yourself as a trusted leader.
- Business Acumen and Organizational Savvy: Understanding how organizations operate, make portfolio decisions, generate value, and link personal contributions to enterprise strategy.
- Critical Thinking and Decision-Making in the Age of AI: Applying critical thinking, evaluating AI outputs, and maintaining human judgment in decision-making.
- AI Fluency for Regulated Work: Leveraging agentic AI, AI-assisted work under GxP, AI-enabled submissions, predetermined change control plans, and human-in-the-loop approaches.
- Leveraging Technology for Advanced Career Journeys: Using AI, agentic AI, virtual reality, learning management systems, gamification, and microlearning to enhance skills and career development.
- Preparing the Future Regulatory Workforce: Building technical literacy and regulatory competencies for emerging technologies, advanced therapeutic modalities, and evolving regulatory expectations.

Project, Program, and Portfolio Management Themes

- Project, Program, and Portfolio Management Best Practices: Executing programs under time and cost pressure, accelerated submissions and critical path management, and cross-functional risk management.
- AI-Enabled Program Management: Leveraging agentic AI to streamline deliverables, improve program management, and enhance project execution.
- Portfolio Decision-Making: Applying portfolio decision-making to prioritize investments, allocate resources, and support strategic leadership.
- Cross-Functional Leadership and Organizational Transformation: Leading cross-functional teams, managing risk, and driving enterprise transformation.
- Emerging Capabilities, Therapeutics, and Technology Integration: Applying project management approaches for emerging therapeutics, technology platforms, and evolving regulatory expectations.

Key Questions to be Addressed

How can life sciences professionals strengthen leadership, critical thinking, AI fluency, and business acumen to drive greater organizational and enterprise impact?

How are AI, agentic AI, and emerging technologies transforming professional development, regulatory work, project management, and workforce evolution while maintaining quality, compliance, and appropriate human oversight?

What project, program, and portfolio management strategies best enable organizations to execute complex development programs under increasing time, cost, resource, and regulatory pressures?

How can organizations strengthen cross-functional leadership, workforce development, succession planning, and organizational transformation to prepare the next generation of life sciences leaders?

How can professionals and organizations build the technical, regulatory, and strategic capabilities needed to support emerging therapeutic modalities, evolving regulatory expectations, and future models of drug development?

TRACK 7: **REGULATORY CMC AND PRODUCT QUALITY**

This track explores science- and risk-based approaches across the product lifecycle, from early product and process development to lifecycle expectations for global regulatory CMC submissions, CGMP compliance, and quality systems. Sessions explore the increasing regulatory complexity of development and manufacturing for global markets, accelerated development timelines, emerging technologies, evolving regulations, changing expectations for manufacturing operations and data integrity, and opportunities to enhance global regulatory harmonization and convergence.

Priority Topics / Themes

- Global Supply Chain and Drug Shortages: Strategies to ensure continuity of manufacturing and prevent shortages amid global supply chain challenges.
- Structured Product Quality Data and Submissions: Leveraging structured data to enable harmonized global CMC dossiers and improve regulatory submissions; use of Quality standards.
- Innovative Technologies in CMC and Quality: Exploring advanced technologies, digital tools, artificial intelligence, and innovation to enhance manufacturing and product quality.
- Regulatory Trends and Substances of Concern: Understanding evolving regulations and approaches for managing materials and substances of concern.
- Global Inspections and Lessons Learned: Insights from regulatory inspections, evolving expectations, and practical takeaways for compliance.
- International Regulatory Collaboration and Harmonization: Updates on collaborative global efforts to harmonize CMC submissions and product quality standards, and regulatory reliance and collaboration initiatives.
- Product Evolution, Site Transfers, and Continuous Improvement: Streamlining CMC Post-approval Changes globally
- CMC Acceleration Strategies: Legislative pathways, regulatory flexibility, and pilots that enable faster development while maintaining quality and safety.
- Quality Maturity Management (QMM) and Evolving Global PQS Assessment Frameworks: Insights into programs supporting evolution of quality systems, promotion of quality culture, and opportunities to streamline regulatory pathways and mitigate supply chain risk.
- Platform Technology and Prior Knowledge: Progress toward a global understanding of opportunities and challenges with an emphasis on real world examples.
- Balancing Speed to Patient and Risk: CMC development strategies and regulatory frameworks that ensure optimal benefit-risk profile for clinical start and marketing approval.

Key Questions to be Addressed

How can global supply chain vulnerabilities be addressed to ensure consistent drug availability and prevent shortages?

What advancements in data structuring and digital submissions are shaping the future of a single global CMC dossier?

How are regulatory agencies evolving expectations around inspections, substances of concern, and harmonization efforts?

What innovative approaches, technologies, and regulatory flexibilities are driving accelerated CMC development while maintaining quality standards?

How can we advance global regulatory harmonization and convergence to support supply chain stability and enhance product quality?

How can science- and risk-based approaches better support overall pharmaceutical quality?

How can product development teams effectively and reliably build a regulatory strategy around a foundation of prior knowledge and ensure confidence from global regulators?

How can industry and regulators establish an optimal approach to efficiently evaluate investigational products by addressing CMC barriers that do not significantly impact patient benefit-risk profiles?

TRACK 8: **REGULATORY POLICY, STRATEGY AND GLOBAL COLLABORATION**

This track explores the evolving global regulatory environment by bringing together regulators, industry, and other stakeholders to examine the laws, regulations, guidelines, and frameworks that shape the development, approval, and lifecycle management of drugs, biologics, medical devices, and combination products. Sessions highlight innovative regulatory strategies, evidence generation, regulatory modernization, accelerated development pathways, global convergence and reliance initiatives, regulatory operations, and collaborative approaches that advance timely patient access to safe and effective therapies. Participants will explore current and emerging regulatory policies, regulatory intelligence, digital and AI-enabled approaches, patient-focused drug development, and best practices that strengthen regulatory decision-making across the product lifecycle.

Priority Topics / Themes

- New Regulatory Programs and Recent Legislative Initiatives: Preparing for and responding to emerging regulatory programs, legislative changes, and policy priorities shaping global drug development and oversight.
- Health Authority Modernization: New review paradigms, innovative regulatory frameworks, inspection and compliance innovations, policy implementation, and measuring regulatory impact.
- Evidence Generation, Patient-Centricity & Emerging Paradigms: Approaches for generating, integrating, and applying evidence, including DHTs, digitally derived endpoints, biomarkers, patient experience data, RWE, AI/ML, and decentralized trials, to support benefit-risk evaluation and regulatory decisions across the product lifecycle.
- Regulatory Applications of Innovative Approaches: Strategies, frameworks, and case examples for applying innovative scientific and technological tools, including model-informed drug development (MIDD), new approach methodologies (NAMs), DHTs, novel endpoints approaches, RWE, and AI/ML across regulatory review, decision-making, and oversight.
- Regulatory Intelligence & Strategy: Best practices, frameworks, and case examples for navigating complex global regulatory requirements, submissions, and labeling, including leveraging AI to inform regulatory strategy, labeling analysis and negotiation, competitive intelligence, regulatory landscape mapping, and proactive health authority engagement.
- Reliance Pathways, Work-sharing, and International Collaboration: Promoting regulatory convergence, reliance, efficiency, and timely availability of medicines.
- Accelerated Development Pathways: Expedited regulatory pathways, innovative trial designs, and development frameworks for unmet medical needs and special populations.
- Regulatory Operations Excellence: Strategies, digital tools, and best practices to optimize end-to-end regulatory operations, including submission planning and management, global dossier lifecycle management, labeling operations, and alignment with evolving regulatory requirements and technologies.
- Special Populations in Health Research and Product Development: Regulatory considerations for rare diseases, pediatrics, chronic conditions, gene therapy, vaccines, ATMPs, and combination products.
- Ensuring Global Access to Medicines: Regulatory, policy and collaborative approaches to improve global access to medical products, including payer and coverage decisions, evolving legislative frameworks, and regulatory strategies that influence availability and access. Manufacturing continuity and operational supply chain considerations are addressed in Track 7.

Key Questions to be Addressed

How is the global regulatory landscape evolving, and what strategies can help organizations navigate increasing complexity while advancing regulatory convergence, reliance, efficiency, and timely access to medicines?

What regulatory innovations, modernization efforts, and operational approaches can improve regulatory review, submissions, compliance, and decision-making across the product lifecycle?

How can organizations generate, integrate, and apply innovative sources of evidence, including RWD, AI/ML, digital health technologies, biomarkers, and patient experience data, to support regulatory decisions and product development?

How are regulators and industry advancing accelerated development pathways, innovative technologies, and regulatory strategies to address unmet medical needs, special populations, and emerging therapeutic modalities?

What regulatory intelligence, strategic planning, and health authority engagement approaches can help organizations make informed decisions, navigate global regulatory requirements, and avoid compliance risks?

TRACK 9: **R&D QUALITY AND COMPLIANCE**

This track explores the evolving landscape of quality and compliance across research and development, emphasizing proactive, risk-based approaches that ensure trial integrity, participant protections, and regulatory compliance across clinical trials, including agile, pragmatic, decentralized, and technology-enabled trial settings. Sessions highlight inspection readiness, global regulatory collaboration, and practical applications of GCP, GVP, GLP, ISO 14155, ICH E6(R3), and ICH E8(R1); foster a culture of quality; strengthen data governance and data reliability; address quality during organizational change; and leverage emerging technologies, including AI/ML, to enhance quality oversight.

Priority Topics / Themes

Regulatory and Compliance

- Inspection Findings: Health Authority trends and findings across GCP, GVP, and medical devices, and emerging inspection approaches, including FDA Remote Regulatory Assessments (RRAs) and Remote Interactive Evaluations (RIEs).
- International Collaboration: Implementing ICH E6(R3) and advancing global collaboration while navigating regulatory harmonization and regional divergence.
- Organizational Structures: Understanding the functions and operations of regulatory authorities, including FDA, MHRA, and other global agencies.

Operations, Change, and Technology

- Mergers and Acquisitions (M&A): Addressing quality considerations during M&A, including due diligence, risk assessment, knowledge retention, and asset handover.
- Operationalizing ICH E6(R3) and ICH E8(R1): Applying Quality by Design (QbD), Risk-Based Quality Management (RBQM), data governance, transparency, and a culture of quality.
- Real World Evidence: Preparing registry and real-world data for inspection based on intended use and regulatory expectations.
- Artificial Intelligence: Leveraging AI/ML to safeguard critical-to-quality (CtQ) factors and strengthen quality management practices.
- AI Governance and Assurance: Ensuring AI/ML is fit for purpose through governance frameworks, audits, inspection findings, trends, and continuous improvement.
- Optimizing Data Quality: Strengthening data reliability in pragmatic, decentralized, and technology-enabled clinical trials.

Key Questions to be Addressed

How can organizations strengthen quality systems and risk-based approaches to improve trial integrity, participant protections, and regulatory compliance across increasingly complex clinical trials?

How are evolving regulations, inspection findings, and global harmonization efforts shaping quality and compliance practices across GCP, GVP, GLP, ISO 14155, and medical devices?

How can organizations leverage AI/ML, Quality by Design, Risk-Based Quality Management, and data governance to enhance quality oversight while ensuring inspection readiness and regulatory compliance?

What operational strategies best support quality and compliance during organizational change, real-world evidence generation, decentralized and technology-enabled clinical trials, and other evolving research environments?

TRACK 10: **STATISTICS, EVIDENCE GENERATION & REAL-WORLD DATA**

This track explores the methodological and statistical approaches that design, analyze, and interpret evidence for regulatory, health technology assessment (HTA), payer, and clinical decision-making. It emphasizes innovative statistical methods, real-world data (RWD), causal inference, external controls, evidence synthesis, Bayesian methods, model-informed drug development, and benefit-risk assessment to strengthen the credibility of evidence across the product lifecycle. While Track 3 focuses on the generation, curation, integration, and operational enablement of data, Track 10 focuses on the analytical frameworks, statistical methodologies, and evidence strategies that transform data into decision-grade evidence. Sessions highlight statistical innovation, AI-enabled evidence generation, patient-centered evidence, trusted data and methods, and cross-disciplinary collaboration to support regulatory submissions, HTA evaluations, and healthcare decision-making.

Priority Topics / Themes

- Causal Inference, External Controls, and Synthetic Comparators: Target-trial emulation; historical trial and RWD controls; hybrid designs; transportability, unmeasured confounding, quantitative bias and sensitivity analyses.
- Evidence Synthesis and Indirect Treatment Comparisons: Network and individual-participant-data meta-analysis; MAIC, STC and cross-design synthesis; heterogeneity, effect modification and regulatory/HTA interpretation.
- Bayesian Methods and Quantitative Decision-Making: Evidence borrowing, adaptive learning, dose selection, subgroup and safety assessment, benefit–risk and development decisions; prior conflict and operating characteristics.
- Innovative Trial Designs and Master Protocols: Adaptive, platform, basket, umbrella, pragmatic and externally augmented trials; nonconcurrent controls, multiplicity, simulation and operational bias.
- Estimands, Missing Data, and Complex Clinical Questions: Treatment discontinuation, rescue medication, switching, competing events and missing-not-at-random assumptions; alignment of objectives, data collection and analysis.
- Synthetic Data, Virtual Populations, and Model-Informed Drug Development: Synthetic patients from historical trials and RWD; QSP, PBPK and disease models integrating multi-omics and biological knowledge; validation and uncertainty quantification.
- AI-Enabled Evidence and the Transformation of Biopharma and Regulation: AI applications in data, endpoints, analytics and evidence synthesis; impact on operating models, statistical roles, regulatory review, governance and policy.
- Putting Global RWD and RWE Guidance into Practice: Operationalizing ICH M14, emerging E23, E6(R3) and regional expectations; data fitness, prespecification, transparency, reproducibility and regulator engagement.
- Decision-Grade RWE Across the Product Lifecycle: RWE for approvals, labeling, post-approval commitments, safety, HTA and payer decisions; successful, unsuccessful and inconclusive case studies.
- Patient-Centered Evidence Across the Product Lifecycle: Patient partnership, PROs, preferences, digital measures and patient-generated data; meaningful effects, missingness, representativeness and decision-maker acceptance.
- Trusted RWD, Methods, and Endpoints Across Studies and Submissions: Data quality, provenance, linkage, phenotype and endpoint validation, analytic methods and software; efficient reuse with reassessment for each context of use.
- Scalable Evidence Ecosystems and Public–Private Collaboration: Federated networks, common data models, interoperability and privacy-enhancing technologies; sustainable governance, cross-border research and reproducible evidence generation.

Key Questions to be Addressed

How can advanced statistical methods, innovative trial designs, and external or synthetic comparators generate reliable evidence while addressing bias, uncertainty, multiplicity, and operational complexity?

How can organizations translate global RWD and RWE guidance into decision-grade evidence that supports regulatory, safety, HTA, payer, and lifecycle decisions?

How are AI, synthetic data, virtual populations, and model-informed approaches transforming evidence generation, statistical practice, regulatory review, and governance?

What data, methods, infrastructure, and partnerships are needed to produce trusted, patient-centered, reproducible evidence across studies, submissions, and global healthcare systems?

TRACK 11: **LIFT SERIES (LINKING INNOVATION, FUNDING, AND TRANSLATION)**

The LIFT Series (Linking Innovation, Funding, and Translation) returns to DIA 2027 after a successful launch in Philadelphia, bringing together emerging innovators, biotech and technology companies, investors, regulators, and life sciences leaders to accelerate the next generation of healthcare solutions. As part of DIA 2027, LIFT will showcase groundbreaking ideas, novel technologies, transformative approaches that are shaping the future of drug development and healthcare, and collaborative partnerships that transform promising ideas into real-world impact.

Priority Topics / Themes

We encourage abstract submissions that explore:

- Startup and entrepreneurial journeys
- Emerging technologies and digital health innovations
- AI-enabled solutions for life sciences
- Venture capital and investment perspectives
- Translating research into commercial products
- Academic-industry collaborations
- Innovation ecosystems
- Scaling new technologies globally
- Regulatory pathways for innovative companies
- Lessons learned from bringing disruptive ideas to market interoperability and privacy-enhancing technologies; sustainable governance, cross-border research and reproducible evidence generation.

Selected submissions may be featured within LIFT Series programming at DIA 2027, providing an opportunity to share your vision with a global community of life sciences professionals, potential partners, investors, and decision-makers.